Artgen’s net profit under IFRS for 6 months of 2026 amounted to ₽24.7 million, a 5.4‑fold decrease compared to ₽132.4 million in the previous year. Revenue increased by 4.8% to ₽879.2 million, compared to ₽838.9 million a year earlier.

Net profit of Artgen Biotech under RAS for 6 months of 2026 amounted to ₽53.6 million, an increase of 19.9% compared to ₽44.7 million in the previous year. Revenue increased by 41.2% to ₽104.9 million, compared to ₽74.3 million a year earlier.

Betuvax, a company within the Arthgen Biotech group, has completed preclinical studies of a new drug Betufeld for the treatment of cat allergies. Studies on mice have confirmed the high specific activity and safety of the drug. Betuvax is currently finalizing the regulatory dossier. Within a year, the company plans to obtain approval from the Ministry of Hea...

Board of Directors of Artgen recommended that dividends be paid for 2025 in the amount of ₽1.2 per ordinary share. The last day of the purchase of securities to receive dividends is June 19, 2026. Dividend yield may amount to 2.17%.